Qi Xiangjun, Li Yanlong, Liu Wei, Wang Yifan, Chen Zhuangzhong, Lin Lizhu
The First Clinical School of Guangzhou University of Chinese Medicine, Guangzhou, China.
The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Front Pharmacol. 2022 Jun 20;13:921385. doi: 10.3389/fphar.2022.921385. eCollection 2022.
Antibody-drug conjugate (ADC) is a promising therapy for solid cancer that has raised global concern. Although several papers have reviewed the current state of ADCs in different solid cancers, a quantitative analysis of the publications in this field is scarce. Publications related to ADC in the field of solid cancer were obtained from the Web of Science Core Collection. Data analyses were performed with VOSviewer 1.6.9, HistCite 2.1, CiteSpace V and package Bibliometrix. A total of 3,482 records were obtained in the holistic field and 1,197 in the clinical field. Steady growth in the number of publications was observed. The United States was the leading contributor in this field. Krop IE was the most influential author. The most productive institution was Genentech Inc., while Mem Sloan Kettering Canc Ctr was the most cited one. The most impactful journal was the . A total of 37 burst references and five burst references were identified between 2017-2022 in the holistic and clinical fields, respectively. Keywords analysis indicated that ADCs research mainly involved breast cancer, triple-negative breast cancer, ovarian cancer, small cell lung cancer, prostate cancer, gastric cancer, and urothelial carcinoma. ADC agents including trastuzumab emtansine, trastuzumab deruxtecan, sacituzumab govitecan, enfortumab vedotin, and rovalpituzumab tesirine were highly studied. Targets including HER2, trophoblast cell-surface antigen, mesothelin, delta-like ligand 3, and nectin-4 were the major concerns. This study analyzed publications concerning ADCs in the field of solid cancer with bibliometric analysis. Further clinical trials of ADCs and designs of the next generation of ADCs are the current focuses of the field. Acquired resistance of ADCs and biomarkers for ADC therapy efficacy monitoring are future concerns.
抗体药物偶联物（ADC）是一种有前景的实体癌治疗方法，已引起全球关注。尽管有几篇论文综述了ADC在不同实体癌中的现状，但该领域出版物的定量分析却很少。从科学网核心合集获取了实体癌领域中与ADC相关的出版物。使用VOSviewer 1.6.9、HistCite 2.1、CiteSpace V和Bibliometrix软件包进行数据分析。在整个领域共获得3482条记录，在临床领域获得1197条记录。观察到出版物数量稳步增长。美国是该领域的主要贡献者。Krop IE是最具影响力的作者。发文量最多的机构是基因泰克公司，而纪念斯隆凯特琳癌症中心是被引用次数最多的机构。最具影响力的期刊是《 》。在2017年至2022年期间，分别在整个领域和临床领域确定了37个突发参考文献和5个突发参考文献。关键词分析表明，ADC研究主要涉及乳腺癌、三阴性乳腺癌、卵巢癌、小细胞肺癌、前列腺癌、胃癌和尿路上皮癌。包括曲妥珠单抗恩坦辛、曲妥珠单抗德鲁替康、戈沙妥珠单抗、恩扎妥昔单抗和洛伐替尼在内的ADC药物得到了深入研究。包括HER2、滋养层细胞表面抗原、间皮素、δ样配体3和NECTIN-4在内的靶点是主要关注点。本研究通过文献计量分析对实体癌领域中有关ADC的出版物进行了分析。ADC的进一步临床试验和下一代ADC的设计是该领域当前的重点。ADC的获得性耐药以及用于监测ADC治疗疗效的生物标志物是未来需要关注的问题。
